SANTA ROSA -- Santa Rosa-based medical device maker TriVascular Technologies, Inc. (Nasdaq: TRIV) had a strong reception on its Wall Street debut Wednesday, as its stock price rose nearly 15 percent.

The stock price at the close of trading was $13.79. TriVascular was initially seeking $100 million on shares priced at $13--$15. But Tuesday the company lowered its expectations to about $89.7 million, based on $12 a share.

TriVascular said in its March 10 prospectus that funds from the IPO would go toward expanded marketing of its abdominal stent graft system as well as paying off a loan from Boston Scientific.

The IPO is set to close April 22, subject to customary closing conditions. The company offered 6.5 million shares of common stock at $12 per share and has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the same price.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated are acting as co-managers.

The company reported a net loss of $50.3 million last year on revenues of $19.5 million. It had a deficit of $238.5 million through last year, and cash and equivalents totaled $38.1 million, according to the prospectus.

In 2005, the company was acquired by Boston Scientific, which later closed TriVascular as a cost-cutting measure. TriVascular returned in 2008 after raising $65 million to re-acquire itself from Boston Scientific.

TriVascular’s Ovation system, which the company describes as the lowest-profile commercially available device for the treatment of abdominal aortic aneurysms, received approval from the  U.S. Food and Drug Administration in October 2012 and by the European Commission in August 2010.  It has been used to treat more than 3,000 patients across 25 countries in clinical trials, according to the company.

TriVascular is the third North Bay company to go public this year, following Novato-based rare-disorder drug developer Ultragenyx Pharmaceutical on Jan. 31 and Santa Rosa-based pharmaceutical developer Ruthigen on March 24.

The Nasdaq exchange overall rose 1.29 percent Wednesday.